IP Verse

Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin

PatentPatent Analysis

EP3337478

IPSEN BIOPHARM
Application Number
EP16758337A
Filing Date
Aug 19, 2016
Status
Granted And Under Opposition
Jul 10, 2020
Grant Date
Aug 12, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3796929B1
EP3758611B1
EP3266456B1

Bibliography

The patent EP3337478B1 was granted to Ipsen Biopharm on Aug 12, 2020 following the initial filing on Aug 19, 2016 under the application number EP16758337A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 12, 2021ADMISSIBLE
SANDOZMay 6, 2021ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents